Hi all,I have been doing some added research on the Syntara...

Hi all,

I have been doing some added research on the Syntara suite of products. The list is much longer than I anticipated. This stock has a huge inventory of discovery to come. I will list what I have found in no particular order.

SNT-5505 for Myelofibrosis

Professor Claire Harrison, Professor of myeloproliferative neoplasms at Guy’s and St Thomas’ NHS Foundation Trust, commented: "This hasn’t been seen before with this class of drug and holds potential for real long-term benefits for MF patients. I look forward to seeing the data mature in the coming months".

"This interim data confirms the excellent safety profile of SNT-5505 and also suggests that the mechanism of SNT-5505 may exert a long-term effect on the disease."

What is interesting is that we all consider myelofibrosis ( bone marrow cancer) in one grouping but in reality there is four groupings that SNT-5505 cover that being Myelodysplastic syndrome/ myelomocytic leukaemia/ post polycythemia vera/ post essential thrombocytopenia.These conditions have been subjected to SNT-5505 are in the current associated program or thought pattern of the Company.

What does SNT-5505 in combination with a chemotherapy agent do in relation to efficacy in Liver Cancer. Improved survival by 45% . In Pancreatic cancer the figure was 35%.

https://pubmed.ncbi.nlm.nih.gov/37640930/

https://www.garvan.org.au/news-resources/news/drug-that-targets-scar-like-tissue-in-tumours-shows-promise-for-aggressive-pancreatic-cancer

SNT-6302 for scar modification.

This is one hot drug. Professor Fiona Wood ( Australian of the year) the most eminent burns consultant in Australia. Remember she treated the Bali bombing victims decades ago says this about the Syntara product.

"This exploratory clinical study has significantly enhanced our understanding of the role of LOX enzymes in scarring and the scar process itself. SNT‐6302 safely inhibits these key enzymes to a significant degree and leads directly to an unprecedented change to the scar composition that we have not seen with any other form of treatment. We estimate that up to 50% of the excess collagen in these patients’ scars has been removed" .

Professor Wood knows that scarring is not skin deep and long term issues can lead to more sinister conditions.

Remember this treatment ointment is applied 3 times a week. That is such an easy application for the patients .

SNT-4728Phase 2 UK trial ends very soon and interim results will be highly interesting. Remember we didn't pay for this trial.I am thinking this may be a lead on to Alzheimer's and Huntingtons disease. Why, well we already have SNT-5131 and this study supports it.

https://pubmed.ncbi.nlm.nih.gov/21075085/

SNT-5131 is a potent inhibitor of SSAO ( Semicarbazide-sensitive amine oxidase) & MAOB ( Monoamine oxidase B ) .

Another interesting pathway for SNT- 5131 is Duchene Muscular Dystrophy
https://pmc.ncbi.nlm.nih.gov/articles/PMC11201281/

Syntara are doing Idiopathic REM sleep behavior disorder (IRBD) studies with Parkinson's disorder.

Are you aware of the cross referencing of this disorder with Lewy body dementia ( Bruce Willis/Rita Hayworth/ Robin Williams) also includes Multiple Systems Atrophy/ Depression and Ischaemic Heart Disease.

Onto SNT-5382 includes potential treatment for chronic kidney disease (chronic renal failure) including idiopathic pulmonary fibrosis and non-alcoholic steatohepatitis.

SNT-8370 has completed IND FDA and is ready for trials for inflammation.

Let's expand on what the Company states for inflammation.

1.Chronic inflammatory diseases

2. Autoimmune disorders

3. Inflammatory skin conditions

4.Respiratory inflammatory diseases

5. Neuroinflammatory conditions

So in conclusion Syntara has many conditions it's proprietary novel small molecule patent protected drugs may influence.

I will ask a question now . Is SNT is undervalued with 4 x phase II candidates MC should be closer to $200m.

I am deeply scientifically across 3 ASX biotech companies. All three are primed for treatments on a variety of conditions mostly neurological, but Syntara is a shining light amongst them.

Why, I believe due to the amount of conditions it could treat.

Would it surprise me for the Company to create an "off" licensed ASX company for SNT 6302. No. Would I do it . Maybe yes to provide a loyalty situation with our current shareholders. I know it's a bit abstract but if you research what the CEO has said on webinars it may provide a clue to the future.

SNT is undervalued in my humble scientific opinion. I will let others ascertain a financial figure my forte is science.

Well done management and team on your endeavours so far. Exciting times ahead.

Kpax